San Diego, California, United States Pacira Pharmaceuticals is the famous Corporate Investor, which was founded in 1989. The main department of described Corporate Investor is located in the San Diego. The venture was found in North America in United States.
The increased amount of exits for fund were in 2019. The important activity for fund was in 2017. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 deals per year.
The typical case for the fund is to invest in rounds with 4 participants. The meaningful sponsors for the fund in investment in the same round are Signet Healthcare Partners, Quaker Partners, OrbiMed. In the next rounds fund is usually obtained by ProMedica Health System, Checkmate Capital.
Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Biotechnology, Life Science. Among the various public portfolio startups of the fund, we may underline TELA Bio For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
Related Funds
| Fund Name | Location |
| Aeternity | Liechtenstein, Oberland, Vaduz |
| APY Ventures | Istanbul, Istanbul, Turkey |
| Avid Ventures | New York, New York, United States |
| Black Capital | - |
| Eastic | Beijing, Beijing, China |
| Formica Ventures | - |
| GX Software | Gelderland, Netherlands, Nijmegen |
| Kunshan Hi-tech Venture Capital | China, Jiangsu, Suzhou |
| Macromill | Chiba Prefecture, Japan, Tateyama |
| MidMark Capital | Morristown, New Jersey, United States |
| Movistar | Community of Madrid, Madrid, Spain |
| OMERS Private Equity | Canada, Ontario, Toronto |
| Theorem Ventures | California, San Francisco, United States |
| Towerview Ventures | - |
| Unity Ventures | Budapest, Hungary |
| Zhenru Investment | Beijing, Beijing, China |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Spine BioPharma | $13M | 28 Mar 2022 | New York, New York, United States | ||
Genascence | $10M | 07 Jan 2022 | - | ||
GeneQuine Biotherapeutics GmbH | $6M | 15 Feb 2021 | Germany, Baden-Württemberg, Germany | ||
AVALON.AI | $1M | 28 Aug 2020 | New York, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Spine BioPharma | $13M | 28 Mar 2022 | New York, New York, United States | ||
Genascence | $10M | 07 Jan 2022 | - | ||
GeneQuine Biotherapeutics GmbH | $6M | 15 Feb 2021 | Germany, Baden-Württemberg, Germany | ||
AVALON.AI | $1M | 28 Aug 2020 | New York, United States |
